SymbolFMS
NameFRESENIUS MEDICAL CARE AG
SectorHEALTH CARE
RegionEurope
Industry-
Address61346 Germany Else-Kroner Strasse 1
Telephone+49 6172 608 2522
Fax
Email
Websitehttp://www.freseniusmedicalcare.com/en/investors/i
IncorporationDE
Incorporated On
Employees
Fiscal Year12/31
Public Since
ExchangesOTC;NASDAQ
Auditor
Audit StatusAUDITED
Reporting StatusU.S. Reporting: SEC Reporting
CIK0001333141
Description

Fresenius Medical Care is the worlds largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.5 million individuals worldwide. Through its network of 3,250 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 270.122 patients around the globe. Fresenius Medical Care is also the worlds leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Additional info from NASDAQ:
Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of September 2021. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the worlds only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.

Additional info from OTC:
Fresenius Medical Care is the worlds largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.5 million individuals worldwide. Through its network of 3,250 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 270.122 patients around the globe. Fresenius Medical Care is also the worlds leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

2026-04-14 10:00

FRESENIUS MEDICAL CARE AG (FMS) Files Form 6-K

Read more
2026-03-18 11:01

New Form 3 - Fresenius Medical Care AG <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001104659-26-030144 <b>Size:</b> 17 KB

Read more
2026-02-24 19:56

Fresenius Medical Care (FMS) Files Form 6-K

Read more
2026-02-24 14:59

New Form IRANNOTICE - Fresenius Medical Care AG <b>Filed:</b> 2026-02-24 <b>AccNo:</b> 0001104659-26-019011 <b>Size:</b> 12 KB

Read more
2026-02-24 11:00

FRESENIUS MEDICAL CARE AG (FMS) Files Form 6-K

Read more
2026-02-23 23:00

Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

Read more
2026-01-23 05:00

Statement from Fresenius Medical Care on Upcoming Winter Storm

Read more
2026-01-19 16:01

Fresenius Medical Care AG (FMCQF) Files Form 6-K

Read more
2026-01-09 06:57

Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

Read more
2025-12-10 16:21

Fresenius Medical Care AG (FMCQF) Files Form 6-K

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT01887262 Control Of Fluid Balance Guided by Body Composition Monitoring in Patients on P… Na Peritoneal Dialysis, Continuous Ambulatory Completed 2013-07-01 2016-07-01 ClinicalTrials.gov
NCT01997385 The Clinical Effects of Korean Adapted APD in Automated Peritoneal Dialysis Pat… Phase4 Renal Insufficiency, Chronic Completed 2012-06-01 2014-06-01 ClinicalTrials.gov
NCT01668628 Quality of Life and Depression in Dialysis Patients Chronic Kidney Disease Stage 5 Completed 2010-08-01 2014-06-01 ClinicalTrials.gov
NCT01315314 Effect of Glucose Degradation Products (GDP) on Endothelial Dysfunction Phase4 Kidney Failure, Chronic Completed 2005-10-01 2008-04-01 ClinicalTrials.gov
Total clinical trials: 4
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Balance, Fresenius Medical Care, Germany Other Phase PHASE4 Kidney Failure, Chronic COMPLETED NCT01315314
KAPD-A Other Phase PHASE4 Renal Insufficiency, Chronic COMPLETED NCT01997385
KAPD-C Other Phase PHASE4 Renal Insufficiency, Chronic COMPLETED NCT01997385
Fluid management based on the clinical information alone Other Approved Peritoneal Dialysis, Continuous Ambulatory COMPLETED NCT01887262
BCM-guided fluid management Other Approved Peritoneal Dialysis, Continuous Ambulatory COMPLETED NCT01887262
Total products: 5